Structured evidence table for Choline Memory Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Choline Memory Meta-Analysis | Various pharmacological and nonpharmacological interventions have been introduced, but the evidence regarding their efficacy, safety, and tolerability is conflicting and inconsistent. | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Choline Memory Meta-Analysis | This could be attributed to a decline in the efficacy of ChE-Is treatment over time, and to the difficulty in treating specific patient categories such as older age groups, or patients with the concomitant presence of conditions such as bradycardia, bronchial asthma, or chronic obstructive pulmonary disease due to the treatment-associated adverse effects (,). | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Choline Memory Meta-Analysis | Studies were classified based on the quality assessment into three categories: low-risk bias (all quality criteria met), moderate-risk bias (one or more quality criteria only partly met), and high-risk bias (one or more quality criteria not met). | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Choline Memory Meta-Analysis | 1 2 3 4 5 6 Dementia is a condition linked to various neurodegenerative diseases, marked by a significant decline in cognitive abilities that affects daily activities (). | 1 | Sagaro Getu Gamo (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis |
| Choline Memory Meta-Analysis | In contrast, BD-II is associated with longer depressive episodes, more pronounced psychomotor retardation, and stronger suicidal ideation [,]. | 4 | Zhang Rongxu (2026) | Differences in biochemical metabolism and cognitive function between bipolar I and bipolar II disorder |
| Choline Memory Meta-Analysis | Consequently, diagnosing based solely on the recognition of manic or hypomanic symptoms carries a substantial risk of misdiagnosis. | 4 | Zhang Rongxu (2026) | Differences in biochemical metabolism and cognitive function between bipolar I and bipolar II disorder |
| Choline Memory Meta-Analysis | Bipolar I disorder is characterised by reward hypersensitivity, which may lead to increased approach behaviours, tendencies toward hypomania or mania, emotional instability, and dysregulation []. | 4 | Zhang Rongxu (2026) | Differences in biochemical metabolism and cognitive function between bipolar I and bipolar II disorder |
| Choline Memory Meta-Analysis | 29 35 7 12 40 12 22 37 Bipolar disorder (BD) is a serious and persistent mood disorder that significantly impairs patients’ social functioning and quality of life []. | 4 | Zhang Rongxu (2026) | Differences in biochemical metabolism and cognitive function between bipolar I and bipolar II disorder |
Source documents